Transgene S.A. (0OCQ.L) LSE
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Transgene S.A.
Address
400, Boulevard Gonthier d’Andernach
Illkirch-Graffenstaden, 67405
France
Phone
33 3 88 27 91 00
Website
Sector
Healthcare
Industry
Biotechnology
Employees
144
First IPO Date
November 05, 2008
Key Executives
| Name | Title | Pay | Year Born |
| Alessandro Riva | Chief Executive Officer & Chairman of the Board | 840,000 | 1960 |
| James Wentworth | Vice President & Chief Business Officer | 0 | 1980 |
| Feriel Marin | Interim Chief Quality Officer | 0 | N/A |
| Gaelle Stadtler | Vice President & Director of Human Resources | 0 | 1984 |
| Lucie Larguier | Vice President & Chief Financial Officer | 0 | 1984 |
| John Felitti | Vice President, General Counsel & Corporate Secretary | 0 | 1970 |
| Christelle Schwoerer | Chief Human Resources Officer | 0 | 1992 |
| Emmanuelle Dochy | Vice President of Medical Affairs & Chief Medical Officer | 0 | 1976 |
| Maurizio Ceppi | Chief Scientific Officer | 0 | 1972 |
| Simone Silva Steiner | Chief Technical Officer | 0 | 1976 |
| Katell Bidet Huang | Head of Translational Medicine | 0 | N/A |
Description
Transgene SA is a biotechnology company focused on the research and development of therapeutic vaccines and oncolytic viruses, with a primary objective to treat cancer and infectious diseases. Its product pipeline includes TG4050, a therapeutic vaccine currently in Phase I clinical trials for ovarian cancer and head and neck cancers that are HPV-negative. Another therapeutic vaccine, TG4001, is undergoing Phase II clinical development for HPV-positive cancers. The company is also advancing oncolytic viruses such as TG6002, which is in Phase I/IIa trials for a variety of solid tumors, including gastrointestinal adenocarcinomas of the stomach, pancreas, and colon, and BT-001, an oncolytic virus in Phase I/II clinical trials for solid tumors. Additionally, Transgene is developing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus intended for solid tumor treatment. The company has established numerous strategic collaborations and licensing agreements with key industry players, including AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, NEC Corporation, SillaJen, Ascend BioPharmaceutical, Valneva, Sanofi, BioInvent, and Randox. Founded in 1979, Transgene SA is headquartered in Illkirch-Graffenstaden, France, and operates as a subsidiary of TSGH SAS.
